Blueprint: Insightful Kinase Inhibitors

Traditional kinase inhibitor screening approaches for cancer have relied on chemical libraries designed to inhibit other targets or treat different diseases. Blueprint Medicines is looking to change that by building a brand new library of kinase inhibitors that it believes will be more selective and potent than inhibitors developed using the other approaches.

In cancer, mutations in protein kinases can cause aberrant expression of the kinase that leads to uncontrolled cell division and proliferation. Drugs that inhibit these aberrant kinases are the focus of many cancer programs...